BioCryst Reports Second Quarter 2024 Financial Results and Provides Business Update
BCRXBioCryst Pharmaceuticals(BCRX) GlobeNewswire News Room·2024-08-05 19:00

—Q2 2024 ORLADEYO net revenue grows 34 percent y-o-y to 108.3million——Full−year2024ORLADEYOrevenueguidanceincreasedto108.3 million— —Full-year 2024 ORLADEYO revenue guidance increased to 420-435million(previously435 million (previously 390-400million)——CompanygeneratesGAAPoperatingprofitof400 million)— —Company generates GAAP operating profit of 8.8 million in second quarter ($21.9 million non-GAAP operating profit)— —Pipeline continues to advance— RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the second quarter ended June 30, 2024, ...